SCHEMBL20183671

SCHEMBL20183671

CCCCC(=O)N(Cc1ccc(-c2ccc(OCC(=O)OCC)cc2)cc1)c1cccc(Br)c1

nearest known ligand 0.69

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
LTB4R2 Q9NPC1 19/20 0.69
CYP2C8 P10632 1/20 0.51
CYP2C9 P11712 1/20 0.51
CYP2C19 P33261 1/20 0.51
PTGDR2 Q9Y5Y4 1/20 0.51
AGTR1 P30556 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18426007 0.90 LTB4R2 (0.80) LTB4R2CYP2C8CYP2C9CYP2C19PTGDR2
SCHEMBL20183613 0.90 LTB4R2 (0.84) LTB4R2CYP2C8CYP2C9CYP2C19PTGDR2
SCHEMBL29562741 0.89 LTB4R2 (0.82) LTB4R2CYP2C8CYP2C9CYP2C19PTGDR2
SCHEMBL20183624 0.89 LTB4R2 (0.69) LTB4R2CYP2C8CYP2C9CYP2C19PTGDR2
SCHEMBL20183475 0.89 LTB4R2 (0.69) LTB4R2CYP2C8CYP2C9CYP2C19PTGDR2
SCHEMBL20183862 0.86 LTB4R2 (0.83) LTB4R2CYP2C8CYP2C9CYP2C19PTGDR2
SCHEMBL18424708 0.86 LTB4R2 (0.73) LTB4R2CYP2C8CYP2C9CYP2C19PTGDR2
SCHEMBL20183492 0.85 LTB4R2 (0.65) LTB4R2CYP2C8CYP2C9CYP2C19PTGDR2
SCHEMBL28229600 0.84 LTB4R2 (0.71) LTB4R2AGTR1
SCHEMBL18425363 0.83 LTB4R2 (0.76) LTB4R2AGTR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3327001-B1 NOVEL COMPOUND HAVING BLT INHIBITORY ACTIVITY AND COMPOSITION, FOR PREVENTING OR TREATING INFLAMMATORY DISEASES, COMPRISING SAME AS ACTIVE INGREDIENT UNIV DONGGUK IND ACAD COOP (KR) 2022-04-13 EP disclosed
CN-108349875-B Compound having BLT inhibitory activity and composition for preventing or treating inflammatory disease comprising the same as active ingredient 东国大学校产学协力团 2021-08-27 CN disclosed
US-20180215706-A1 NOVEL COMPOUND HAVING BLT INHIBITORY ACTIVITY AND COMPOSITION, FOR PREVENTING OR TREATING INFLAMMATORY DISEASES, COMPRISING SAME AS ACTIVE INGREDIENT DONGGUK UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) 2018-08-02 US disclosed
EP-3327001-A1 NOVEL COMPOUND HAVING BLT INHIBITORY ACTIVITY AND COMPOSITION, FOR PREVENTING OR TREATING INFLAMMATORY DISEASES, COMPRISING SAME AS ACTIVE INGREDIENT Dongguk University Industry-Academic Cooperation Foundation (KR) 2018-05-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180215706-A1 NOVEL COMPOUND HAVING BLT INHIBITORY ACTIVITY AND COMPOSITION, FOR PREVENTING OR TREATING INFLAMMATORY DISEASES, COMPRISING SAME AS ACTIVE INGREDIENT LTB4R2, CYSLTR2, LTB4R LTB4R2 1/4885CYP2C8 3474/4885CYP2C9 4116/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.